AR and prostate carcinoma: While advanced prostate cancer in the hormone-sensitive setting can often be controlled with androgen deprivation therapy (ADT) in combination with androgen receptor (AR) signaling pathway inhibitors (ARPI), with or without the addition of chemotherapy for several years, disease progression to castration resistance eventually occurs in the majority of patients2.